Asthma

Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences

Retrieved on: 
Monday, April 29, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Bank of America, Congress, DEEP, ATS, Arrowhead, Antiviral Research, RESULTS, Conference, Asthma, EAS, NLA, National Lipid Association, AN, American Thoracic Society

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
    2024 RBC Capital Markets Global Healthcare Conference – May 14-15, 2024
    BofA Securities 2024 Healthcare Conference – May 13-16, 2024
    TIDES USA 2024 – May 14-17, 2024
    American Thoracic Society (ATS) 2024 International Conference – May 17-22, 2024
    Title: A First-in-Human Study of ARO-RAGE, a Novel Inhaled RNA-Interference Therapy for Asthma
    37th International Conference on Antiviral Research (ICAR2024) – May 20-24, 2024
    European Atherosclerosis Society (EAS) 92nd Congress – May 26-29, 2024
    Title: PLOZASIRAN (ARO-APOC3), DECREASES APOC3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH MIXED DYSLIPIDEMIA: MUIR FINAL RESULTS
    Title: PLOZASIRAN (ARO-APOC3), AN INVESTIGATIONAL RNAI THERAPEUTIC, DEMONSTRATES PROFOUND AND DURABLE REDUCTIONS IN APOC-3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG), SHASTA-2 FINAL RESULTS
    Title: ZODASIRAN SILENCES HEPATIC ANGPTL3 LEADING TO DEEP AND DURABLE REDUCTIONS IN ATHEROGENIC LIPIDS AND LIPOPROTEINS IN MIXED DYSLIPIDEMIA PATIENTS: FINAL RESULTS FROM ARCHES-2, DOUBLE-BLIND PERIOD
    2024 National Lipid Association (NLA) Scientific Sessions – May 30 – June 2, 2024
    Title: ENCORE - PLOZASIRAN (ARO-APOC3), DECREASES APOC3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH MIXED DYSLIPIDEMIA: MUIR FINAL RESULTS
    Title: ENCORE - PLOZASIRAN (ARO-APOC3), AN INVESTIGATIONAL RNAI THERAPEUTIC, DEMONSTRATES PROFOUND AND DURABLE REDUCTIONS IN APOC-3 AND TRIGLYCERIDES (TG) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG), SHASTA-2 FINAL RESULTS
    Presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

Global Airway Management Devices Market Analysis and Forecast, 2023-2033: Competitive Landscape, Ecosystem, Reimbursement Scenario, Patent Analysis, Partnerships, Collaborations, & Business Expansions - ResearchAndMarkets.com

Retrieved on: 
Monday, April 29, 2024
General Health, Health, Medical Devices, Chronic obstructive pulmonary disease, Airway management, Competitive landscape, Catheter, Anesthesia, Asthma, Growth, Prevalence, COPD, Airline

North America is poised to emerge as a major contributor to the growth of the airway management devices market.

Key Points: 
  • North America is poised to emerge as a major contributor to the growth of the airway management devices market.
  • What are the major market drivers, challenges and opportunities in the global airway management devices market and their case studies?
  • What is the market share of the leading segments and sub-segments of the global airway management devices market?
  • How will each segment of the global airway management devices market grow during the forecast period?

Global Skin Allergy Testing Market Report 2024: Revenue Data for 2020-2022, Estimated Figures for 2023, and Forecasts for 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 26, 2024
Health, Other Health, Asthma, Allergic rhinitis, Allergic conjunctivitis, Drug allergy, Anaphylaxis, Hospital, Cosmetics

This report provides detailed information about the global skin allergy testing market.

Key Points: 
  • This report provides detailed information about the global skin allergy testing market.
  • It also analyzes the size of the skin allergy testing market based on test types, applications and end users.
  • Based on applications, the skin allergy testing market is segmented into allergic rhinitis, allergic asthma, drug allergy, allergic conjunctivitis, anaphylaxis and others.
  • Analysis of global market trends, featuring revenue data for 2020-2022, estimated figures for 2023, and forecasts for 2028.

Aptar Reports First Quarter 2024 Results

Retrieved on: 
Thursday, April 25, 2024
Packaging, Pharmaceutical, Health, Manufacturing, Decongestant, Central Time, Investment, Emergency medicine, ERP, Therapy, Translation, Acquisition, AptarGroup, Central nervous system, Allergic rhinitis, Asthma, Growth, Beauty, Interest

Aptar Pharma had an increase in reported sales of 14% and cores sales of 13% over the prior year quarter.

Key Points: 
  • Aptar Pharma had an increase in reported sales of 14% and cores sales of 13% over the prior year quarter.
  • Sales improved for the Injectables division, rebounding from the Enterprise Resource Planning (ERP) implementation headwind that impacted the first quarter results of 2023.
  • Aptar Beauty’s reported sales were flat compared to the prior year quarter, and with currency effects core sales were down slightly.
  • There will be a conference call held on Friday, April 26, 2024 at 8:00 a.m. Central Time to discuss the company’s first quarter results for 2024.

ComEd Joins Bronzeville Community to Unveil New Public EV Chargers

Retrieved on: 
Thursday, April 25, 2024
Other Energy, Automotive, EV, Electric Vehicles, Environment, Alternative Energy, Green Technology, Energy, DOE, EXC, EVS, Respiratory Health Association, Investment, Level 2, Greenhouse gas, CEJA, Commonwealth, MUD, Sustainable energy, Electricity, Transport, Illinois College of Optometry, Exelon, Patient, Commonwealth Edison, Faculty, ICO, Student, Illinois College, Atmosphere, Asthma, Climate, Air pollution, Renewable energy

Because densely populated areas have limited access to EV charging, and fewer parking lots to accommodate public charging infrastructure, curbside charging will be critical for EV adoption in these areas.

Key Points: 
  • Because densely populated areas have limited access to EV charging, and fewer parking lots to accommodate public charging infrastructure, curbside charging will be critical for EV adoption in these areas.
  • Since the start of this pilot in 2022, the five Bronzeville chargers installed throughout the community have served nearly 300 unique drivers, and more than 2,800 charging sessions.
  • The chargers are strategically placed throughout the Bronzeville community to support individuals living in multi-unit dwellings (MUDs), including apartment complexes and condominium buildings.
  • As a ComEd Community of the Future , Bronzeville is a key example of the clean energy transformation happening in Illinois.

Clarity Pediatrics Announces Expansion of Virtual Pediatric ADHD Platform and $10M in Funding

Retrieved on: 
Monday, April 22, 2024
Managed Care, General Health, Professional Services, Family, Telemedicine, Virtual Medicine, Consumer, Mental Health, Health Technology, Children, Practice Management, Finance, Health, Kaiser Permanente, American Academy, Investment, ARR, Medicaid, ADHD, BPT, Ginger, Pediatrics (journal), UCSF, Stanford University, Patient, Physician, Medicine, City, Allergy, Function (mathematics), Asthma, Growth, Prevalence, Rock Health, Nursing

Clarity Pediatrics , a digital health company reimagining pediatric chronic care, announced today the expansion of their pediatric ADHD platform and $10M in seed funding led by Rethink Impact with participation from Homebrew and Maverick Ventures .

Key Points: 
  • Clarity Pediatrics , a digital health company reimagining pediatric chronic care, announced today the expansion of their pediatric ADHD platform and $10M in seed funding led by Rethink Impact with participation from Homebrew and Maverick Ventures .
  • This investment supports Clarity Pediatrics’ launch of new clinical service lines, further development of their innovative care platform, and geographic expansion.
  • The cornerstone of Clarity Pediatrics’ approach to ADHD care is Behavioral Parent Training (BPT), recommended by the American Academy of Pediatrics for families of children ages 5 to 12 with mild-moderate ADHD.
  • Clarity Pediatrics makes pediatric ADHD care 10x more accessible and 20x more affordable: families have access to next-day appointments, including for ADHD diagnostic screening and medication-related services, and pay an average co-pay of $15 per session.

Mundipharma and Vectura announce plans to reformulate flutiform® (fluticasone propionate/formoterol fumarate) pressurised metered-dose inhaler (pMDI) as a commitment to reducing the product’s carbon footprint

Retrieved on: 
Tuesday, April 16, 2024
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Medication package insert, Climate change, NHS, Isocyanate, EEA, European, European Parliament, Carbon, Life, Climate, Environment, Council, Patient, World Asthma Day, Medicine, Fluticasone, Multimedia, HFA, Gas, NHS England, Asthma, Pharmaceutical industry

Mundipharma and Vectura will now progress development of the reformulation of flutiform® (fluticasone propionate/formoterol fumarate) following long-term collaboration, planning and lab-scale development work.

Key Points: 
  • Mundipharma and Vectura will now progress development of the reformulation of flutiform® (fluticasone propionate/formoterol fumarate) following long-term collaboration, planning and lab-scale development work.
  • The reformulation will ultimately ensure a comparable effective product for patients and further reduce its impact on the environment.
  • This new collaboration will revitalise the efforts to identify and switch to a more environmentally friendly propellant.
  • “At Vectura, our priority is to ensure that patients prescribed fluticasone propionate/formoterol fumarate pMDI can continue to have access to this treatment.

Global Oxygen Cylinders and Concentrators Market Analysis and Forecasts, 2020-2024 and 2025-2030: Internet of Things (IoT) Connectivity Transforms Oxygen Concentrators into Smart Healthcare Devices - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 11, 2024
Health, Medical Supplies, Medical Devices, USD, Epidemiology, Internet of things, Porter's five forces analysis, Miniaturization, Investment, Chronic obstructive pulmonary disease, SWOT, Skin, Death, Health care, Vital signs, Patient safety, Mask, Incidence, Sleep apnea, Patient, Asthma, Prevalence, IHME, Medication, COPD, Medical device

The Global Oxygen Cylinders and Concentrators market showcased growth at a CAGR of 5.87% during 2020-2023.

Key Points: 
  • The Global Oxygen Cylinders and Concentrators market showcased growth at a CAGR of 5.87% during 2020-2023.
  • The Oxygen Cylinders and Concentrators Market is expected to continue growing as the global population ages and the prevalence of respiratory diseases increases, driving the need for effective oxygen therapy solutions.
  • As the global population ages and environmental factors contribute to respiratory health issues, the need for oxygen cylinders and concentrators continues to grow.
  • Technological advancements in portable oxygen cylinders and concentrators have transformed respiratory care, offering greater convenience, mobility, and usability for patients.

FASENRA approved for treatment of children aged 6 to 11 with severe asthma

Retrieved on: 
Thursday, April 11, 2024
Health, FDA, General Health, Research, Science, Pharmaceutical, Biotechnology, Efficacy, Safety, Gastroenterology, HES, Chronic obstructive pulmonary disease, Sinusitis, Social media, Polyp (medicine), Pharmacokinetics, Rheumatology, Conference call, Asthma, TATE, AstraZeneca, FY, Hypereosinophilic syndrome, Death, ClinicalTrials.gov, Dermatology, Conference, COPD, Webcast, Growth, Disease, Vasculitis, Respiratory Medicine, EGPA, Immunology, Metabolism, Diagnosis, Biomarker, PD, Biopharmaceutical, Ageing, Pharmaceutical industry

TATE was an open-label, Phase III trial evaluating the safety of FASENRA in children aged 6 to 11 years with severe eosinophilic asthma.

Key Points: 
  • TATE was an open-label, Phase III trial evaluating the safety of FASENRA in children aged 6 to 11 years with severe eosinophilic asthma.
  • The Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death.
  • Benralizumab in children with severe eosinophilic asthma: pharmacokinetics and long-term safety (TATE study).
  • Severe uncontrolled asthma in children: practical approach on diagnosis and management.

NIMML Institute Presents Pioneering Research on Immunometabolic Mechanisms Related to the Pharmacological Activation of LANCL Receptors at Immunology2024, the Annual Meeting of the American Association of Immunologists

Retrieved on: 
Wednesday, April 10, 2024
Health Technology, Other Health, Technology, Pharmaceutical, Oncology, Mental Health, Philanthropy, Infectious Diseases, Genetics, Artificial Intelligence, Clinical Trials, Foundation, Biotechnology, Science, Research, Health, Eosinophilia, Bronchial hyperresponsiveness, NIMML, Swelling, Choline, PBMC, Gastrointestinal tract, Macrophage, Fibrosis, Red, Atopic dermatitis, Brain, TNF, Inflammation, Phenotype, Abstract, Glycolysis, Lupus, T helper 17 cell, IBD, AAI, Psoriasis, OVA, MASH, Plasma, Fed, Ulcerative colitis, Mouse, COL1A1, Microglia, McCormick Place, Therapy, Carbon tetrachloride, HDM, Immunoglobulin E, IL-6, Medicine, Asthma, House, Neutrophil, Patient, Phagocytosis, Ovalbumin, Rheumatoid arthritis, LANCL2, CDAA, UC

The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.

Key Points: 
  • The AAI meeting will take place at McCormick Place in Chicago, Illinois from May 3 to May 7, 2024.
  • “We are pleased to present our most recent findings related to the immunometabolic mechanisms of activation of LANCL receptors in inflammation & immunology at this year’s AAI Annual Meeting,” said Dr. Josep Bassaganya-Riera, President and Founding Director of NIMML.
  • NImmune’s portfolio includes first and best-in-class omilancor and NIM-1324, two oral, once-daily agonistic therapeutics that bind and activate the LANCL2 pathway.
  • Title: Pharmacological activation of LANCL2 provides immunometabolic support for the restoration of cognitive function markers in a mouse model of Alzheimer’s disease.